A real world study analysing clinical outcomes of pembrolizumab plus chemotherapy in non-squamous metastatic NSCLC elderly patients at US oncology practices
Latest Information Update: 14 Oct 2020
Price :
$35 *
At a glance
- Drugs Carboplatin (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress